Merck cuts ties to Moderna's early-phase KRAS vaccine, leaving mRNA specialist to mull next steps

Merck has dumped Moderna’s mutant KRAS vaccine mRNA-5671. The action, which comes shortly after Merck closed enrollment in a phase 1 trial, leaves Moderna pondering the next steps for the program.